291 related articles for article (PubMed ID: 20091131)
1. No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.
Vahteristo P; Koski TA; Näätsaari L; Kiuru M; Karhu A; Herva R; Sallinen SL; Vierimaa O; Björck E; Richard S; Gardie B; Bessis D; Van Glabeke E; Blanco I; Houlston R; Senter L; Hietala M; Aittomäki K; Aaltonen LA; Launonen V; Lehtonen R
Fam Cancer; 2010 Jun; 9(2):245-51. PubMed ID: 20091131
[TBL] [Abstract][Full Text] [Related]
2. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
[TBL] [Abstract][Full Text] [Related]
3. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
5. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of cancer in patients with fumarate hydratase germline mutation.
Lehtonen HJ; Kiuru M; Ylisaukko-Oja SK; Salovaara R; Herva R; Koivisto PA; Vierimaa O; Aittomäki K; Pukkala E; Launonen V; Aaltonen LA
J Med Genet; 2006 Jun; 43(6):523-6. PubMed ID: 16155190
[TBL] [Abstract][Full Text] [Related]
7. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
8. Prospective Detection of Germline Mutation of Fumarate Hydratase in Women With Uterine Smooth Muscle Tumors Using Pathology-based Screening to Trigger Genetic Counseling for Hereditary Leiomyomatosis Renal Cell Carcinoma Syndrome: A 5-Year Single Institutional Experience.
Rabban JT; Chan E; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 May; 43(5):639-655. PubMed ID: 30741757
[TBL] [Abstract][Full Text] [Related]
9. Strong family history of uterine leiomyomatosis warrants fumarate hydratase mutation screening.
Tolvanen J; Uimari O; Ryynänen M; Aaltonen LA; Vahteristo P
Hum Reprod; 2012 Jun; 27(6):1865-9. PubMed ID: 22473397
[TBL] [Abstract][Full Text] [Related]
10. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
11. A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata.
Shi Y; Xu Y; Wang C; Chen Y; Ren X; Kang Y; Wang C
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981015
[TBL] [Abstract][Full Text] [Related]
12. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
Toro JR; Nickerson ML; Wei MH; Warren MB; Glenn GM; Turner ML; Stewart L; Duray P; Tourre O; Sharma N; Choyke P; Stratton P; Merino M; Walther MM; Linehan WM; Schmidt LS; Zbar B
Am J Hum Genet; 2003 Jul; 73(1):95-106. PubMed ID: 12772087
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.
Vocke CD; Ricketts CJ; Merino MJ; Srinivasan R; Metwalli AR; Middelton LA; Peterson J; Yang Y; Linehan WM
Genes Chromosomes Cancer; 2017 Jun; 56(6):484-492. PubMed ID: 28196407
[TBL] [Abstract][Full Text] [Related]
15. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
Wei MH; Toure O; Glenn GM; Pithukpakorn M; Neckers L; Stolle C; Choyke P; Grubb R; Middelton L; Turner ML; Walther MM; Merino MJ; Zbar B; Linehan WM; Toro JR
J Med Genet; 2006 Jan; 43(1):18-27. PubMed ID: 15937070
[TBL] [Abstract][Full Text] [Related]
16. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.
Zhang L; Walsh MF; Jairam S; Mandelker D; Zhong Y; Kemel Y; Chen YB; Musheyev D; Zehir A; Jayakumaran G; Brzostowski E; Birsoy O; Yang C; Li Y; Somar J; DeLair D; Pradhan N; Berger MF; Cadoo K; Carlo MI; Robson ME; Stadler ZK; Iacobuzio-Donahue CA; Joseph V; Offit K
Hum Mutat; 2020 Jan; 41(1):103-109. PubMed ID: 31444830
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
19. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]